Zinc supplementation for improving glucose handling in pre-diabetes: A double blind randomized placebo controlled pilot study

Islam, MR; Attia, J; Ali, L; McEvoy, M; Selim, S; Sibbritt, D; Akhter, A; Akter, S; Peel, R; Faruque, O; Mona, T; Lona, H; Milton, AH

Zinc supplementation for improving glucose handling in pre-diabetes: A double blind randomized placebo controlled pilot study

Islam, MR Attia, J Ali, L McEvoy, M Selim, S Sibbritt, D

Akhter, A Akter, S Peel, R Faruque, O Mona, T Lona, H Milton, AH

Permalink

Publication Type:: Journal Article
Citation:: Diabetes Research and Clinical Practice, 2016, 115 pp. 39 - 46
Issue Date:: 2016-05-01

Closed Access

	Filename	Description	Size
	1-s2.0-S0168822716300353-main.pdf	Published Version	485.83 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Islam, MR	en_US
dc.contributor.author	Attia, J	en_US
dc.contributor.author	Ali, L	en_US
dc.contributor.author	McEvoy, M	en_US
dc.contributor.author	Selim, S	en_US
dc.contributor.author	Sibbritt, D https://orcid.org/0000-0003-3561-9447	en_US
dc.contributor.author	Akhter, A	en_US
dc.contributor.author	Akter, S	en_US
dc.contributor.author	Peel, R	en_US
dc.contributor.author	Faruque, O	en_US
dc.contributor.author	Mona, T	en_US
dc.contributor.author	Lona, H	en_US
dc.contributor.author	Milton, AH	en_US
dc.date.available	2016-03-04	en_US
dc.date.issued	2016-05-01	en_US
dc.identifier.citation	Diabetes Research and Clinical Practice, 2016, 115 pp. 39 - 46	en_US
dc.identifier.issn	0168-8227	en_US
dc.identifier.uri	http://hdl.handle.net/10453/122747
dc.description.abstract	© 2016 Elsevier Ireland Ltd. Aims: There are a number of studies showing that zinc supplementation may improve glucose handling in people with established diabetes. We sought to investigate whether this zinc-dependent improvement in glucose handling could potentially be harnessed to prevent the progression of pre-diabetes to diabetes. In this double-blind randomized placebo-controlled trial, we determined participants' fasting blood glucose levels, (FBG) and Homeostasis Model Assessment (HOMA) parameters (beta cell function, insulin sensitivity and insulin resistance) at baseline and after 6 months of zinc supplementation. Methods: The Bangladesh Institute of Health Sciences Hospital (BIHS) (Mirpur, Dhaka, Bangladesh) database was used to identify 224 patients with prediabetes, of whom 55 met the inclusion criteria and agreed to participate. The participants were randomized either to the intervention or control group using block randomization. The groups received either 30 mg zinc sulphate dispersible tablet or placebo, once daily for six months. Results: After six months, the intervention group significantly improved their FBG concentration compared to the placebo group (5.37 ± 0.20 mmol/L vs 5.69 ± 0.26, p < 0.001) as well as compared to their own baseline (5.37 ± 0.20 mmol/L vs 5.8 ± 0.09, p < 0.001). Beta cell function, insulin sensitivity and insulin resistance all showed a statistically significant improvement as well. Conclusion: To our knowledge this is the first trial to show an improvement in glucose handling using HOMA parameters in participants with prediabetes. Larger randomized controlled trials are warranted to confirm these findings and to explore clinical endpoints.	en_US
dc.relation.ispartof	Diabetes Research and Clinical Practice	en_US
dc.relation.isbasedon	10.1016/j.diabres.2016.03.010	en_US
dc.subject.classification	Endocrinology & Metabolism	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Prediabetic State	en_US
dc.subject.mesh	Insulin Resistance	en_US
dc.subject.mesh	Zinc Sulfate	en_US
dc.subject.mesh	Glucose	en_US
dc.subject.mesh	Blood Glucose	en_US
dc.subject.mesh	Hypoglycemic Agents	en_US
dc.subject.mesh	Treatment Outcome	en_US
dc.subject.mesh	Pilot Projects	en_US
dc.subject.mesh	Double-Blind Method	en_US
dc.subject.mesh	Dietary Supplements	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	Female	en_US
dc.subject.mesh	Male	en_US
dc.title	Zinc supplementation for improving glucose handling in pre-diabetes: A double blind randomized placebo controlled pilot study	en_US
dc.type	Journal Article
utslib.citation.volume	115	en_US
utslib.for	1103 Clinical Sciences	en_US
utslib.for	1117 Public Health and Health Services	en_US
utslib.for	1701 Psychology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHSP - Health Services and Practice
utslib.copyright.status	closed_access
pubs.publication-status	Published	en_US
pubs.volume	115	en_US

Abstract:

© 2016 Elsevier Ireland Ltd. Aims: There are a number of studies showing that zinc supplementation may improve glucose handling in people with established diabetes. We sought to investigate whether this zinc-dependent improvement in glucose handling could potentially be harnessed to prevent the progression of pre-diabetes to diabetes. In this double-blind randomized placebo-controlled trial, we determined participants' fasting blood glucose levels, (FBG) and Homeostasis Model Assessment (HOMA) parameters (beta cell function, insulin sensitivity and insulin resistance) at baseline and after 6 months of zinc supplementation. Methods: The Bangladesh Institute of Health Sciences Hospital (BIHS) (Mirpur, Dhaka, Bangladesh) database was used to identify 224 patients with prediabetes, of whom 55 met the inclusion criteria and agreed to participate. The participants were randomized either to the intervention or control group using block randomization. The groups received either 30 mg zinc sulphate dispersible tablet or placebo, once daily for six months. Results: After six months, the intervention group significantly improved their FBG concentration compared to the placebo group (5.37 ± 0.20 mmol/L vs 5.69 ± 0.26, p < 0.001) as well as compared to their own baseline (5.37 ± 0.20 mmol/L vs 5.8 ± 0.09, p < 0.001). Beta cell function, insulin sensitivity and insulin resistance all showed a statistically significant improvement as well. Conclusion: To our knowledge this is the first trial to show an improvement in glucose handling using HOMA parameters in participants with prediabetes. Larger randomized controlled trials are warranted to confirm these findings and to explore clinical endpoints.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/122747